Voyager Therapeutics (NASDAQ:VYGR) Shares Gap Up to $9.26

Voyager Therapeutics, Inc. (NASDAQ:VYGR)’s stock price gapped up prior to trading on Tuesday . The stock had previously closed at $9.26, but opened at $9.89. Voyager Therapeutics shares last traded at $9.99, with a volume of 221,271 shares traded.

Wall Street Analysts Forecast Growth

VYGR has been the topic of a number of research analyst reports. HC Wainwright initiated coverage on Voyager Therapeutics in a research report on Tuesday, March 19th. They issued a “buy” rating and a $30.00 target price on the stock. Guggenheim initiated coverage on Voyager Therapeutics in a research report on Tuesday. They issued a “buy” rating and a $22.00 target price on the stock. Citigroup initiated coverage on Voyager Therapeutics in a research report on Thursday, March 7th. They set a “buy” rating and a $16.00 price objective on the stock. StockNews.com upgraded Voyager Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, March 9th. Finally, Wells Fargo & Company upgraded Voyager Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $9.00 to $14.00 in a research report on Tuesday, January 2nd. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $19.33.

Voyager Therapeutics Price Performance

The firm has a fifty day moving average price of $8.33 and a two-hundred day moving average price of $7.84. The stock has a market capitalization of $519.11 million, a PE ratio of 3.09 and a beta of 0.96.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings results on Wednesday, February 28th. The company reported $1.25 earnings per share for the quarter, topping the consensus estimate of ($0.59) by $1.84. Voyager Therapeutics had a return on equity of 63.89% and a net margin of 52.93%. The firm had revenue of $90.06 million for the quarter, compared to the consensus estimate of $4.95 million. On average, research analysts expect that Voyager Therapeutics, Inc. will post -1.64 earnings per share for the current fiscal year.

Institutional Trading of Voyager Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Armistice Capital LLC boosted its position in Voyager Therapeutics by 1.4% during the 4th quarter. Armistice Capital LLC now owns 4,236,000 shares of the company’s stock valued at $35,752,000 after acquiring an additional 58,000 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Voyager Therapeutics by 1.9% in the 4th quarter. Vanguard Group Inc. now owns 2,529,668 shares of the company’s stock worth $21,350,000 after purchasing an additional 47,711 shares in the last quarter. BlackRock Inc. boosted its position in shares of Voyager Therapeutics by 200.7% in the 2nd quarter. BlackRock Inc. now owns 2,477,400 shares of the company’s stock worth $28,366,000 after purchasing an additional 1,653,613 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Voyager Therapeutics by 19.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 932,231 shares of the company’s stock worth $7,869,000 after purchasing an additional 153,291 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its position in shares of Voyager Therapeutics by 13.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 901,465 shares of the company’s stock worth $6,951,000 after purchasing an additional 104,144 shares in the last quarter. Institutional investors own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.